Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials
Ascidian Therapeutics, Inc
Summary
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Description
The prescreening process will be used to help determine the initial eligibility and interest of potential participants in ACDN-01 clinical trials by conducting assessments of key eligibility criteria before the clinical trial screening procedures are performed.
Eligibility
- Age range
- 5+ years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: * Presence of mutations in the ABCA4 gene * ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy) Key Exclusion Criteria: * The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy * Retinal disease other than ABCA4-related retinopathy * Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude…
Interventions
- Diagnostic TestPrescreening Assessments
Various genetic and visual assessments.
Locations (8)
- University of San FranciscoSan Francisco, California
- Vitreo Retinal AssociatesGainesville, Florida
- Wilmer Eye Institute at John HopkinsBaltimore, Maryland
- Massachusetts Eye and EarBoston, Massachusetts
- University of Michigan Kellogg Eye CenterAnn Arbor, Michigan
- Cincinnati Eye InstituteCincinnati, Ohio